Last reviewed · How we verify
NCT06025604
ACTIVPROSEIN : Professional Activity After Breast Cancer
trial in Breast Cancer Female in 578 participants. Status unknown.
13 September 2025
Quick facts
| Lead sponsor | University Hospital, Grenoble |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 578 |
| Start date | 14 September 2023 |
| Primary completion | 13 September 2025 |
| Estimated completion | 13 September 2025 |
| Sites | 1 location across France |
Conditions studied
- Breast Cancer Female — all drugs for Breast Cancer Female →
- Return to Work — all drugs for Return to Work →
Sponsor
University Hospital, Grenoble
Who can join
Adults 18 to 60, female only, with Breast Cancer Female or Return to Work. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Breast cancer is, in term of incidence, the first cancer among women in France and worldwide. This incidence is increasing, particularly among young women during their professional activity. Those observations raise de question of return to work of those patients, and, broadly, of the post cancer life and former activities recovery. The objective of the study is to identify any factor influencing time from diagnosis to return to work (type of treatment, side effects, residual symptoms, medical staff support, occupational physician monitoring, individual or group supportive therapy, adapted physical activity, alternative therapeutics ..), and the main modalities of return to work (part or full time, professional redeployment). To identify those factors, barriers or supports, would enable the implementation of concrete actions and programs, promoting return to work, and to a free disease life for those patients. The main objective is to identify psycho social factors involved in the time from diagnosis to return to any modality of work, until 24 month after localized breast cancer care, in Grenoble University Hospital (Michalon and Voiron included) Secondary objectives are to identify psycho social factors involved in the time from diagnosis to return to work, part time, full time, and redeployment, respectively, until 24 month after localized breast cancer care, in Grenoble University Hospital (Michalon and Voiron included)
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06025604
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Breast Cancer Female
Currently open trials in the same condition.
- NCT07505797 — ATUSA Ultrasound Diagnostic Imaging for Breast Lesions Evaluation (AUDIBLE) · recruiting
- NCT07198724 — ERADICATE: A Phase Ib/II Study of Elacestrant Plus Trastuzumab Deruxtecan in Patients With CDK4/6 Inhibitor and Endocrin · Phase 1, PHASE2 · recruiting
- NCT07331506 — Validation of the Oncoliq Test for the Early Detection of Breast Cancer. · recruiting
- NCT07214883 — UCF MammoChat: Image Repository · recruiting
- NCT07120100 — Transcranial Magnetic Stimulation for Chemotherapy-Induced Peripheral Neuropathy in Breast and Gynecologic Cancer Surviv · NA · recruiting
Other University Hospital, Grenoble trials
Trials by the same sponsor.
- NCT07479225 — Circulating Cell-Free DNA for Brain Abscess Diagnosis: A Pilot Study · NA · not yet recruiting
- NCT07477613 — Implantable Brain-Computer Interface for Upper-Limb Recovery After Stroke · NA · not yet recruiting
- NCT07379372 — Bladder Overactivity and Post-Botulinum Toxin Telemonitoring · NA · not yet recruiting
- NCT07166991 — Anesthesia sTrategy foR Organ Procurement In braiN dEath · Phase 3 · recruiting
- NCT07367880 — The Monument Test : A New Tool for Assessing the Ability to Name and Identify Unique Entities. (TeDIMO) · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06025604 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University Hospital, Grenoble
- Last refreshed: 15 September 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06025604.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing